Skip to content
drillr.ai
Sign up

MRK

Merck & Co., Inc.

NYSE · Healthcare · Drug Manufacturers - General · US

$143.67
−1.56%
Ask drillr

  • Sep 28, 2026, 09:56 UTC

    MSD appointed Vidhya Sundaram as Associate Vice President of Global Technology Centres and Lead of its Hyderabad Tech Centre.

    Source:

  • Sep 28, 2026, 06:32 UTC

    Daiichi Sankyo withdrew its US accelerated approval application for the small cell lung cancer drug ifinatamab deruxtecan after determining it did not meet the conditions required for approval.

    Source:

  • Sep 28, 2026, 05:30 UTC

    Kenya is preparing to manufacture alimatravir, an investigational once-monthly oral HIV-prevention medicine developed by MSD, according to President William Ruto.

    Source:

  • Sep 27, 2026, 16:00 UTC

    US Senators Elizabeth Warren, Ron Wyden and Richard Blumenthal questioned Health Secretary Robert F. Kennedy Jr. on September 24 over an alleged break in his ethics pledges concerning Gardasil litigation interests.

    Source:

  • Sep 25, 2026, 20:30 UTC

    Daiichi Sankyo and Merck voluntarily withdrew the U.S. Biologics License Application seeking accelerated approval of ifinatamab deruxtecan for adults with extensive-stage small cell lung cancer whose disease progressed on or after platinum-based chemotherapy.

    Source:

  • Sep 24, 2026, 21:58 UTC

    The FDA approved Merck & Co.'s Welireg (belzutifan) in combination with Eisai's Lenvima (lenvatinib) for advanced clear-cell renal cell carcinoma following treatment with a PD-(L)1 inhibitor.

    Source:

  • Sep 24, 2026, 10:45 UTC

    Merck announced that Remigromig met its primary endpoint in a trial for diabetic macular edema (DME).

    Source:

  • Sep 23, 2026, 23:59 UTC

    Summit Therapeutics and Akeso revealed new study findings for ivonescimab that impressed Wall Street amid dueling data with a rival Merck medication.

    Source:

  • Sep 23, 2026, 12:17 UTC

    Justin Gunn was appointed President, Endocrinology at Corcept Therapeutics effective October 1, 2026.

  • Sep 22, 2026, 10:45 UTC

    The U.S. FDA approved an update to the U.S. product label for Merck's WINREVAIR (sotatercept-csrk) to include data from the Phase 3 HYPERION trial in adults recently diagnosed with pulmonary arterial hypertension.

    Source:

  • Sep 21, 2026, 10:45 UTC

    Japan's Ministry of Health, Labour and Welfare approved Merck's KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph) for subcutaneous administration across all KEYTRUDA indications approved in Japan.

    Source:

  • Sep 18, 2026, 10:55 UTC

    The European Medicines Agency's Committee for Medicinal Products for Human Use adopted a positive opinion recommending approval of Merck's KEYTRUDA (pembrolizumab) in combination with Padcev (enfortumab vedotin-ejfv) as perioperative treatment for adults with resectable muscle-invasive bladder cancer.

    Source:

  • Sep 14, 2026, 14:15 UTC

    Moderna and Merck announced that a personalized mRNA cancer vaccine combined with an immunotherapy drug succeeded in a late-stage trial for skin cancer.

    Source:

  • Sep 14, 2026, 10:16 UTC

    Perspective Therapeutics announced a clinical trial collaboration and supply agreement with Merck to evaluate [212Pb]PSV359 in combination with Keytruda (pembrolizumab) in FAP-α positive solid tumors.

    Source:

  • Sep 13, 2026, 13:30 UTC

    The International Consortium of Investigative Journalists published the findings of its yearlong 'Cancer Calculus' investigation into global access to Merck & Co's cancer drug Keytruda.

    Source:

  • Sep 13, 2026, 01:45 UTC

    Merck's Keytruda was evaluated as monotherapy and in combination with Trodelvy in the Merck-sponsored Evoke-03/Keynote-D46 phase 3 trial in previously untreated PD-L1-high non-small cell lung cancer, with results presented at the 2026 World Conference on Lung Cancer.

    Source:

  • Sep 11, 2026, 03:55 UTC

    In US after-hours trading on September 11, 2026, most pharmaceutical and biotech stocks rose, with Eli Lilly up 0.03%, Johnson & Johnson up 0.32%, Merck up 0.09%, Novartis up 0.14%, AstraZeneca up 0.38% and Novo Nordisk up 0.11%.

    Source:

  • Sep 10, 2026, 07:00 UTC

    MSD inaugurated a new 2.5 lakh sq. ft Technology Centre in Hitech City, Hyderabad, strengthening its global technology and digital capabilities network.

    Source:

  • Sep 9, 2026, 08:02 UTC

    Merck announced the commercial launch in China of its RSV monoclonal antibody clerosavir (Anfuchang) for preventing RSV lower respiratory tract infections in newborns and infants.

    Source:

  • Sep 3, 2026, 23:53 UTC

    Electroninks, Merck, and Qualipoly Chemical formed a strategic partnership to build an advanced packaging ecosystem for semiconductor customers.

    Source:

  • Sep 3, 2026, 15:24 UTC

    Cipla's U.S. unit entered an exclusive partnership with Qilu Pharmaceutical to license a biosimilar of Merck's Keytruda for the U.S. market.

    Source:

  • Aug 26, 2026, 04:45 UTC

    Four Democratic senators, led by Elizabeth Warren, sent a letter to Health Secretary Robert F. Kennedy Jr. questioning his disclosures regarding a $50 million settlement by Merck over Gardasil vaccine litigation, in which Kennedy had a financial interest before taking office.

    Source:

  • Aug 20, 2026, 06:48 UTC

    Shares of CSPC Pharmaceutical Group surged over 15% in morning trading on August 20, 2026, driven by positive Phase 3 results of Moderna and Merck's personalized mRNA cancer therapy intismeran.

    Source:

  • Aug 19, 2026, 19:38 UTC

    Biopharma stocks including AbbVie, Amgen, Eli Lilly, Johnson & Johnson, and Merck rallied on Wednesday, with Merck jumping 12.4%.

    Source:

  • Aug 19, 2026, 10:46 UTC

    Merck and Moderna announced that the Phase 3 clinical trial of Intismeran met its primary endpoint, showing the vaccine prevents melanoma recurrence.

    Source:
← PreviousPage 2Next →